Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
Amyloid Fibrils03:03

Amyloid Fibrils

12.0K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

NPJ Parkinson's disease·2026
Same author

Genome-wide association study of copy number variations in Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

The PD COMM Process Evaluation: Describing Interventions and Implementation in a UK Pragmatic Randomised Controlled Trial of Speech and Language Therapy for People With Parkinson's-Related Dysarthria.

International journal of language & communication disorders·2025
Same author

The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT.

Health technology assessment (Winchester, England)·2024
Same author

Genome-wide association study of copy number variations in Parkinson's disease.

medRxiv : the preprint server for health sciences·2024
Same author

Association of Body Mass Index and Parkinson Disease: A Bidirectional Mendelian Randomization Study.

Neurology·2024
Same journal

Rheumatoid arthritis: previously untreated early disease.

BMJ clinical evidence·2016
Same journal

Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema.

BMJ clinical evidence·2016
Same journal

Subarachnoid haemorrhage (spontaneous aneurysmal).

BMJ clinical evidence·2016
Same journal

Malaria: fluid therapy in severe disease.

BMJ clinical evidence·2016
Same journal

Age-related macular degeneration: anti-vascular endothelial growth factor treatment.

BMJ clinical evidence·2016
Same journal

MRSA: treating people with infection.

BMJ clinical evidence·2016
See all related articles

Related Experiment Video

Updated: Feb 9, 2026

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.4K

Parkinson's disease.

Carl E Clarke1, A Peter Moore

  • 1University of Birmingham, Birmingham, UK.

BMJ Clinical Evidence
|May 21, 2009
PubMed
Summary
This summary is machine-generated.

This systematic review evaluates treatments for Parkinson's disease, including drug therapies, surgery, and rehabilitation. It provides evidence on the effectiveness and safety of various interventions for early and advanced stages of the disease.

More Related Videos

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
10:32

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

56.3K
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.9K

Related Experiment Videos

Last Updated: Feb 9, 2026

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.4K
Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
10:32

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

56.3K
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.9K

Area of Science:

  • Neurology
  • Evidence-Based Medicine
  • Clinical Pharmacology

Background:

  • Parkinson's disease affects approximately 1% of adults.
  • The median survival after diagnosis is 9 years.
  • Effective management strategies are crucial for improving patient outcomes.

Purpose of the Study:

  • To systematically review the effects of drug treatments for early-stage Parkinson's disease.
  • To assess interventions for motor complications in levodopa-treated patients.
  • To evaluate surgical, nursing, and rehabilitation treatments for later-stage Parkinson's disease.

Main Methods:

  • Systematic review of literature up to November 2006.
  • Inclusion of systematic reviews, RCTs, and observational studies.
  • Inclusion of safety alerts from regulatory agencies (FDA, MHRA).

Main Results:

  • 59 relevant studies were identified and included.
  • GRADE evaluation was used to assess the quality of evidence for interventions.
  • Data on effectiveness and safety of numerous interventions were compiled.

Conclusions:

  • The review synthesizes evidence on interventions including drug therapies (e.g., dopamine agonists, MAO-B inhibitors), surgery (e.g., deep brain stimulation), and allied health interventions (e.g., physiotherapy, occupational therapy).
  • Information on the effectiveness and safety of these diverse treatments is presented.
  • This review serves as a resource for clinicians managing Parkinson's disease.